The cost of Morphabond is not publicly disclosed by the manufacturer, Mallinckrodt Pharmaceuticals. As an ex vivo gene therapy, its pricing structure would likely be complex, influenced by manufacturing costs, clinical outcomes, and patient access programs. [1][2]
How is Morphabond administered?
Morphabond is an ex vivo gene therapy, meaning cells are collected from the patient, genetically modified outside the body, and then reinfused [3]. This process involves several steps, including cell collection, gene insertion, and cell expansion before administration. The therapy targets Fabry disease, a rare genetic disorder. [3][4]
What is Fabry disease?
Fabry disease is an inherited disorder that results from a deficiency in the enzyme alpha-galactosidase A (α-Gal A). This deficiency leads to the buildup of a fatty substance called globotriaosylceramide (Gb3) in various tissues throughout the body. The accumulation of Gb3 can cause progressive damage to organs such as the kidneys, heart, and nervous system, leading to a range of symptoms including pain, kidney failure, heart problems, and stroke [4].
How does gene therapy work for Fabry disease?
Gene therapy aims to correct the underlying genetic defect causing Fabry disease. In the case of Morphabond, this involves delivering a functional gene that enables the patient's cells to produce the missing alpha-galactosidase A enzyme. By restoring enzyme activity, the therapy seeks to prevent or reduce the accumulation of Gb3 and thereby mitigate the long-term health consequences of the disease [3][4].
What is the difference between Morphabond and enzyme replacement therapy?
Enzyme replacement therapy (ERT) for Fabry disease involves regularly infusing patients with a manufactured version of the alpha-galactosidase A enzyme. This provides a temporary solution, as the body continues to break down the infused enzyme, requiring ongoing treatments. Gene therapy, like Morphabond, aims for a more permanent correction by enabling the patient's own cells to produce the enzyme, potentially reducing the need for lifelong treatments [3][4].
Who is developing Morphabond?
Morphabond is being developed by Mallinckrodt Pharmaceuticals. [1]